Email Alert RSS
Volume 14 Issue 3
May  2023
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2023  >  14(3): 638-645
LIU Mohan, ZHOU Xingtong, SUN Qiang. Research Progress on Bone Metastasis of Breast Cancer: from Basic to Clinical Research[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(3): 638-645. doi: 10.12290/xhyxzz.2022-0600
Citation: LIU Mohan, ZHOU Xingtong, SUN Qiang. Research Progress on Bone Metastasis of Breast Cancer: from Basic to Clinical Research[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(3): 638-645. doi: 10.12290/xhyxzz.2022-0600
shu

Research Progress on Bone Metastasis of Breast Cancer: from Basic to Clinical Research

doi: 10.12290/xhyxzz.2022-0600

  • Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds:

National High Level Hospital Clinical Research Funding 2022-PUMCH-B-038

More Information
  • Corresponding author: SUN Qiang, E-mail: xhsunq@163.com
  • Received Date: 2022-10-18
  • Accepted Date: 2022-12-02
    • Available Online: 2022-12-29
  • Publish Date: 2023-05-30
    Abstract
  • Bone is the most common metastatic site of advanced breast cancer. Bone related events caused by bone metastasis seriously affect the quality of life and survival time of patients. Therefore, in order to improve the quality of life and prolong the survival time of breast cancer patients with bone metastases, it is of great clinical value to investigate the occurrence and development mechanism of bone metastases, explore early diagnosis methods, and pursue abundant and effective treatment methods and drugs for bone metastases. This article mainly reviews the new research progress of bone metastasis of breast cancer from the aspects of molecular mechanism, imaging and biological diagnosis methods, systematic treatment, in order to provide more reference for clinical diagnosis and treatment.
    • FullText(HTML)
  • loading
    • References(63)
  • [1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71: 209-249. doi:  10.3322/caac.21660
    [2] Ording AG, Heide-Jorgensen U, Christiansen CF, et al. Site of metastasis and breast cancer mortality: a Danish nationwide registry-based cohort study[J]. Clin Exp Metastasis, 2017, 34: 93-101. doi:  10.1007/s10585-016-9824-8
    [3] Awolaran O, Brooks SA, Lavender V. Breast cancer osteomimicry and its role in bone specific metastasis; an integrative, systematic review of preclinical evidence[J]. Breast, 2016, 30: 156-171. doi:  10.1016/j.breast.2016.09.017
    [4] DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69: 438-451. doi:  10.3322/caac.21583
    [5] Wang R, Zhu Y, Liu X, et al. The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage Ⅳ breast cancer[J]. BMC Cancer, 2019, 19: 1091. doi:  10.1186/s12885-019-6311-z
    [6] Shinoda Y, Sawada R, Yoshikawa F, et al. Factors related to the quality of life in patients with bone metastases[J]. Clin Exp Metastasis, 2019, 36: 441-448. doi:  10.1007/s10585-019-09983-0
    [7] Yong M, Jensen AÖ, Jacobsen JB, et al. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007)[J]. Breast Cancer Res Treat, 2011, 129: 495-503. doi:  10.1007/s10549-011-1475-5
    [8] Cleeland C, von Moos R, Walker MS, et al. Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer[J]. Support Care Cancer, 2016, 24: 3557-3565. doi:  10.1007/s00520-016-3154-x
    [9] Paget S. The distribution of secondary growths in cancer of the breast. 1889[J]. Cancer Metastasis Rev, 1989, 8: 98-101. http://jcp.bmj.com/lookup/external-ref?access_num=2673568&link_type=MED&atom=%2Fjclinpath%2F61%2F5%2F570.atom
    [10] Pece S, Tosoni D, Confalonieri S, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content[J]. Cell, 2010, 140: 62-73. doi:  10.1016/j.cell.2009.12.007
    [11] Massagué J, Obenauf AC. Metastatic colonization by circulating tumour cells[J]. Nature, 2016, 529: 298-306. doi:  10.1038/nature17038
    [12] Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis[J]. Science, 2011, 331: 1559-1564. doi:  10.1126/science.1203543
    [13] Mohme M, Riethdorf S, Pantel K. Circulating and disseminated tumour cells-mechanisms of immune surveillance and escape[J]. Nat Rev Clin Oncol, 2017, 14: 155-167. doi:  10.1038/nrclinonc.2016.144
    [14] Walker ND, Patel J, Munoz JL, et al. The bone marrow niche in support of breast cancer dormancy[J]. Cancer Lett, 2016, 380: 263-271. doi:  10.1016/j.canlet.2015.10.033
    [15] Wu X, Li F, Dang L, et al. RANKL/RANK System-Based Mechanism for Breast Cancer Bone Metastasis and Related Therapeutic Strategies[J]. Front Cell Dev Biol, 2020, 8: 76. doi:  10.3389/fcell.2020.00076
    [16] Deng R, Zhang HL, Huang JH, et al. MAPK1/3 kinase-dependent ULK1 degradation attenuates mitophagy and promotes breast cancer bone metastasis[J]. Autophagy, 2021, 17: 3011-3029. doi:  10.1080/15548627.2020.1850609
    [17] Zuo H, Yang D, Wan Y. Fam20C Regulates Bone Resorption and Breast Cancer Bone Metastasis through Osteopontin and BMP4[J]. Cancer Res, 2021, 81: 5242-5254. doi:  10.1158/0008-5472.CAN-20-3328
    [18] Sun J, Huang J, Lan J, et al. Overexpression of CENPF correlates with poor prognosis and tumor bone metastasis in breast cancer[J]. Cancer Cell Int, 2019, 19: 264. doi:  10.1186/s12935-019-0986-8
    [19] Pang X, Gong K, Zhang X, et al. Osteopontin as a multifaceted driver of bone metastasis and drug resistance[J]. Pharmacol Res, 2019, 144: 235-244. doi:  10.1016/j.phrs.2019.04.030
    [20] Hofbauer LC, Bozec A, Rauner M, et al. Novel approaches to target the microenvironment of bone metastasis[J]. Nat Rev Clin Oncol, 2021, 18: 488-505. doi:  10.1038/s41571-021-00499-9
    [21] Xu WH, Liu ZB, Yang C, et al. Expression of dickkopf-1 and beta-catenin related to the prognosis of breast cancer patients with triple negative phenotype[J]. PLoS One, 2012, 7: e37624. doi:  10.1371/journal.pone.0037624
    [22] Wu K, Feng J, Lyu F, et al. Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer[J]. Nat Commun, 2021, 12: 5196. doi:  10.1038/s41467-021-25473-y
    [23] 翟士军, 张玉娜, 米宝明, 等. SPECT/CT融合骨显像对乳腺癌骨转移的诊断价值[J]. 中国辐射卫生, 2016, 25: 746-748, 752. doi:  10.13491/j.cnki.issn.1004-714x.2016.06.037

    Zhai SJ, Zhang YN, Mi BM, et al. The Diagnostic Value of SPECT/CT Fusion Bone Imaging for Bone Metastases of Breast Cancer[J]. Zhongguo Fushe Weisheng, 2016, 25: 746-748, 752. doi:  10.13491/j.cnki.issn.1004-714x.2016.06.037
    [24] Kuji I, Yamane T, Seto A, et al. Skeletal standardized uptake values obtained by quantitative SPECT/CT as an osteoblastic biomarker for the discrimination of active bone metastasis in prostate cancer[J]. Eur J Hybrid Imaging, 2017, 1: 2. doi:  10.1186/s41824-017-0006-y
    [25] Zhao Z, Pi Y, Jiang L, et al. Deep neural network based artificial intelligence assisted diagnosis of bone scintigraphy for cancer bone metastasis[J]. Sci Rep, 2020, 10: 17046. doi:  10.1038/s41598-020-74135-4
    [26] Paydary K, Seraj SM, Zadeh MZ, et al. The Evolving Role of FDG-PET/CT in the Diagnosis, Staging, and Treatment of Breast Cancer[J]. Mol Imaging Biol, 2019, 21: 1-10. http://www.onacademic.com/detail/journal_1000040230568610_2e47.html
    [27] van Es SC, Velleman T, Elias SG, et al. Assessment of Bone Lesions with (18)F-FDG PET Compared with (99m)Tc Bone Scintigraphy Leads to Clinically Relevant Differences in Metastatic Breast Cancer Management[J]. J Nucl Med, 2021, 62: 177-183. doi:  10.2967/jnumed.120.244640
    [28] Damle NA, Bal C, Bandopadhyaya GP, et al. The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan[J]. Jpn J Radiol, 2013, 31: 262-269. doi:  10.1007/s11604-013-0179-7
    [29] Choi J, Raghavan M. Diagnostic imaging and image-guided therapy of skeletal metastases[J]. Cancer Control, 2012, 19: 102-112. doi:  10.1177/107327481201900204
    [30] Choi J, Gyamfi J, Jang H, et al. The role of tumor-associated macrophage in breast cancer biology[J]. Histol Histopathol, 2018, 33: 133-145. http://d.wanfangdata.com.cn/periodical/cd19a6171cf085ce1cb4411ac0cf77b0
    [31] Daldrup-Link HE, Golovko D, Ruffell B, et al. MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles[J]. Clin Cancer Res, 2011, 17: 5695-5704. doi:  10.1158/1078-0432.CCR-10-3420
    [32] Shih YY, Hsu YH, Duong TQ, et al. Longitudinal study of tumor-associated macrophages during tumor expansion using MRI[J]. NMR Biomed, 2011, 24: 1353-1360. doi:  10.1002/nbm.1698
    [33] Makela AV, Gaudet JM, Foster PJ. Quantifying tumor associated macrophages in breast cancer: a comparison of iron and fluorine-based MRI cell tracking[J]. Sci Rep, 2017, 7: 42109. doi:  10.1038/srep42109
    [34] 杨志, 杨贵生, 李宁, 等. 全身骨显像联合CA15-3和CEA检测对乳腺癌骨转移的诊断价值[J]. 中华肿瘤防治杂志, 2016, 23: 1229-1123. doi:  10.16073/j.cnki.cjcpt.2016.18.005

    Yang Z, Yang GS, Li N, et al. Diagnostic value of combined whole body bone scintigraphy and serum CA15-3, CEA in breast cancer with bone metastases[J]. Zhonghua Zhongliu Fangzhi Zazhi, 2016, 23: 1229-1123. doi:  10.16073/j.cnki.cjcpt.2016.18.005
    [35] Yazdani A, Dorri S, Atashi A, et al. Bone Metastasis Prognostic Factors in Breast Cancer[J]. Breast Cancer (Auckl), 2019, 13: 1178223419830978.
    [36] Fakhari A, Gharepapagh E, Dabiri S, et al. Correlation of cancer antigen 15-3 (CA15-3) serum level and bony metastases in breast cancer patients[J]. Med J Islam Repub Iran, 2019, 33: 142. http://doc.paperpass.com/foreign/rgArti20194820470.html
    [37] Sarvari BK, Sankara Mahadev D, Rupa S, et al. Detection of Bone Metastases in Breast Cancer (BC) Patients by Serum Tartrate-Resistant Acid Phosphatase 5b (TRACP 5b), a Bone Resorption Marker and Serum Alkaline Phosphatase (ALP), a Bone Formation Marker, in Lieu of Whole Body Skeletal Scintigraphy with Technetium99m MDP[J]. Indian J Clin Biochem, 2015, 30: 66-71.
    [38] 吴春娇, 马丽霞, 朱晶, 等. 联合检测乳腺癌骨转移患者中尿Ⅰ型胶原氨基末端肽和Ⅰ型胶原羧基末端肽的临床意义[J]. 中华肿瘤杂志, 2016, 38: 693-697.

    Wu CJ, Ma LX, Zhu J, et al. Clinical significance of combined detection of urine NTX and serum ICTP for breast cancer patients with bone metastases[J]. Zhonghua Zhongliu Zazhi, 2016, 38: 693-697.
    [39] Zuo CT, Yin DC, Fan HX, et al. Study on diagnostic value of P1NP and beta-CTX in bone metastasis of patients with breast cancer and the correlation between them[J]. Eur Rev Med Pharmacol Sci, 2019, 23: 5277-5284.
    [40] Wong MHF, Stockler MR, Pavlakis N. Bisphosphonates and other bone agents for breast cancer[J]. Cochrane Database Syst Rev, 2012(2): CD003474. http://esmoopen.bmj.com/lookup/external-ref?access_num=22336790&link_type=MED&atom=%2Fesmoopen%2F1%2F2%2Fe000037.atom
    [41] Aft R, Naughton M, Trinkaus K, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial[J]. Lancet Oncol, 2010, 11: 421-428. doi:  10.1016/S1470-2045(10)70054-1
    [42] Zagzag J, Hu MI, Fisher SB, et al. Hypercalcemia and cancer: Differential diagnosis and treatment[J]. CA Cancer J Clin, 2018, 68: 377-386. doi:  10.3322/caac.21489
    [43] Sun W, Ge K, Jin Y, et al. Bone-Targeted Nanoplatform Combining Zoledronate and Photothermal Therapy To Treat Breast Cancer Bone Metastasis[J]. ACS Nano, 2019, 13: 7556-7567. doi:  10.1021/acsnano.9b00097
    [44] Iranikhah M, Wilborn TW, Wensel TM, et al. Denosumab for the Prevention of Skeletal-Related Events in Patients with Bone Metastasis from Solid Tumor[J]. Pharmacotherapy, 2012, 32: 274-284. doi:  10.1002/j.1875-9114.2011.01092.x
    [45] Gómez-Aleza C, Nguyen B, Yoldi G, et al. Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells[J]. Nat Commun, 2020, 11: 6335. doi:  10.1038/s41467-020-20138-8
    [46] Vadhan-Raj S, von Moos R, Fallowfield LJ, et al. Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid[J]. Ann Oncol, 2012, 23: 3045-3051. doi:  10.1093/annonc/mds175
    [47] Diel I, Ansorge S, Hohmann D, et al. Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany[J]. Support Care Cancer, 2020, 28: 5223-5233. doi:  10.1007/s00520-020-05357-5
    [48] Barton MK. Denosumab an option for patients with bone metastasis from breast cancer[J]. Ca Cancer J Clin, 2011, 61: 135-136. doi:  10.3322/caac.20116
    [49] Gnant M, Pfeiler G, Steger GG, et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20: 339-351. doi:  10.1016/S1470-2045(18)30862-3
    [50] Coleman R, Finkelstein DM, Barrios C, et al. Adjuvant denosumab in early breast cancer (D-CARE): an interna-tional, multicentre, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2020, 21: 60-72. doi:  10.1016/S1470-2045(19)30687-4
    [51] Oruç Z, Kaplan MA, Arslan Ç. An update on the currently available and future chemotherapy for treating bone metastases in breast cancer patients[J]. Expert Opin Pharmacother, 2018, 19: 1305-1316. doi:  10.1080/14656566.2018.1504922
    [52] Vashum Y, Kottaiswamy A, Bupesh G, et al. Inhibitory Effects of Cathepsin K Inhibitor (ODN-MK-0822) on the Paracrine Pro-Osteoclast Factors of Breast Cancer Cells[J]. Curr Mol Pharmacol, 2021, 14: 1134-1145. doi:  10.2174/1874467214666210211162118
    [53] Clézardin P. Therapeutic targets for bone metastases in breast cancer[J]. Breast Cancer Res, 2011, 13: 207. doi:  10.1186/bcr2835
    [54] De Felice M, Lambert D, Holen I, et al. Effects of Src-kinase inhibition in cancer-induced bone pain[J]. Mol Pain, 2016, 12: 1744806916643725. doi:  10.1177_1744806916643725.pdf
    [55] Paul D, Vukelja SJ, Ann Holmes F, et al. Randomized phase-Ⅱ evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients[J]. NPJ Breast Cancer, 2019, 5: 36. doi:  10.1038/s41523-019-0132-8
    [56] Schott AF, Barlow WE, Van Poznak CH, et al. Phase Ⅱ studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622[J]. Breast Cancer Res Treat, 2016, 159: 87-95. doi:  10.1007/s10549-016-3911-z
    [57] Hesse E, Schr der S, Brandt D, et al. Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness[J]. JCI Insight, 2019, 5: e125543.
    [58] Jaschke N, Kleymann A, Hofbauer LC, et al. Dorsomorphin: A novel inhibitor of Dickkopf-1 in breast cancer[J]. Biochem Biophys Res Commun, 2020, 524: 360-365. doi:  10.1016/j.bbrc.2020.01.106
    [59] Tanja S, Vivek V, Robert F, et al. Randomized phase Ⅱ trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy[J]. Radiother Oncol, 2018, 128: 274-282. doi:  10.1016/j.radonc.2018.04.030
    [60] Sprave T, Verma V, Förster R, et al. Local response and pathologic fractures following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy for spinal metastases-a randomized controlled trial[J]. BMC Cancer, 2018, 18: 859. doi:  10.1186/s12885-018-4777-8
    [61] Suominen MI, Rissanen JP, Kakonen R, et al. Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis[J]. J Natl Cancer Inst, 2013, 105: 908-916. doi:  10.1093/jnci/djt116
    [62] Takalkar A, Adams S, Subbiah V. Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone[J]. Exp Hematol Oncol, 2014, 3: 23. doi:  10.1186/2162-3619-3-23
    [63] Ueno NT, Tahara RK, Fujii T, et al. Phase Ⅱ study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer[J]. Cancer Med, 2020, 9: 1025-1032. doi:  10.1002/cam4.2780
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (749) PDF downloads(160) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return